

# SCIENTIFIC REPORTS



OPEN

## Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells

Cynthia Morata-Tarifa<sup>1,2</sup>, Gema Jiménez<sup>1,2,3</sup>, María A. García<sup>1,2,4</sup>, José M. Entrena<sup>5,6</sup>, Carmen Griñán-Lisón<sup>1,2</sup>, Margarita Aguilera<sup>2,7</sup>, Manuel Picon-Ruiz<sup>1,2,8</sup> & Juan A. Marchal<sup>1,2,3</sup>

Cancer stem cells are responsible for tumor progression, metastasis, therapy resistance and cancer recurrence, doing their identification and isolation of special relevance. Here we show that low adherent breast and colon cancer cells subpopulations have stem-like properties. Our results demonstrate that trypsin-sensitive (TS) breast and colon cancer cells subpopulations show increased ALDH activity, higher ability to exclude Hoechst 33342, enlarged proportion of cells with a cancer stem-like cell phenotype and are enriched in sphere- and colony-forming cells *in vitro*. Further studies in MDA-MB-231 breast cancer cells reveal that TS subpopulation expresses higher levels of *SLUG*, *SNAIL*, *VIMENTIN* and *N-CADHERIN* while show a lack of expression of *E-CADHERIN* and *CLAUDIN*, being this profile characteristic of the epithelial-to-mesenchymal transition (EMT). The TS subpopulation shows *CXCL10*, *BMI-1* and *OCT4* upregulation, differing also in the expression of several miRNAs involved in EMT and/or cell self-renewal such as miR-34a-5p, miR-34c-5p, miR-21-5p, miR-93-5p and miR-100-5p. Furthermore, *in vivo* studies in immunocompromised mice demonstrate that MDA-MB-231 TS cells form more and bigger xenograft tumors with shorter latency and have higher metastatic potential. In conclusion, this work presents a new, non-aggressive, easy, inexpensive and reproducible methodology to isolate prospectively cancer stem-like cells for subsequent biological and preclinical studies.

The cancer stem cell (CSC) model posits that tumors are maintained by a subpopulation of cells that self-renew and yield heterogeneous progeny with reduced proliferative potential<sup>1,2</sup>. Different molecular mechanisms activated in normal stem cells are also involved in CSC self-renewal, including the expression of certain embryonic stem cells-transcription factors (ES-TFs)<sup>3</sup> or the similar regulation of several signaling pathways<sup>4,5</sup>. Additionally, short non-coding miRNAs are also able to modulate gene expression programs to maintain self-renewal in normal and CSCs<sup>6</sup>.

It is important to note that CSCs also underlie drug resistance, tumor recurrence and metastasis<sup>1,2,7</sup>. Drug resistance and tumor recurrence showed by CSCs are mainly explained by the overexpression of multidrug resistance

<sup>1</sup>Biopathology and Medicine Regenerative Institute (IBIMER), University of Granada, Granada, Spain. <sup>2</sup>Biosanitary Institute of Granada (ibs.GRANADA), University Hospitals of Granada-University of Granada, Granada, Spain.

<sup>3</sup>Department of Human Anatomy and Embryology, University of Granada, Granada, Spain. <sup>4</sup>Department of

Oncology, University Hospital Virgen de las Nieves, Granada, Spain. <sup>5</sup>Institute of Neuroscience, Biomedical Research

Center, University of Granada, Granada, Spain. <sup>6</sup>Animal Behavior Research Unit, Scientific Instrumentation Center,

University of Granada, Granada, Spain. <sup>7</sup>Department of Microbiology, University of Granada, Granada, Spain.

<sup>8</sup>Braman Family Breast Cancer Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA. Correspondence and requests for materials should be addressed to M.P.-R. (email: m.piconruiz@miami.edu) or J.A.M. (email: jmarchal@ugr.es)

(MDR) membrane proteins and the enzyme aldehyde dehydrogenase (ALDH), or their ability to maintain a quiescent state<sup>8</sup>. On the other hand, metastasis is one of the most crucial steps in cancer progression and the main cause of mortality<sup>1</sup>. During local invasion and distant metastasis, the associated cancer cells typically develop alterations in their shape as well as in their attachment to other cells and to the extracellular matrix<sup>9</sup>. Metastatic cancer cells are characterized for suffering an epithelial-to-mesenchymal transition (EMT), a process by which cancer cells lose their attachment to the epithelial niche and acquire a mesenchymal phenotype<sup>10</sup>. These cells then are transported through the vasculature and are disseminated to anatomically distant organ sites where are able to establish new neoplastic growths<sup>11,12</sup>.

The relevance of this cancer cell subpopulation has yield to develop methodologies for their identification and isolation. Breast CSCs are characterized by the phenotype CD44<sup>+</sup>/CD24<sup>low/-</sup><sup>13,14</sup>, while the expression of the cell surface proteins CD133, CD44 and/or CD326 is related with colon CSCs properties<sup>15–17</sup>. Other CSCs characteristics that have been extensively used for their identification and isolation are their high ALDH activity and ability to exclude Hoechst 33342, which is used to determine the side population (SP) phenotype<sup>1,18–21</sup>. However, the isolation of CSCs based on all of these properties requires the fluorescence-activated cell sorting (FACS) method, an expensive and aggressive technique.

As it has been reported previously, cancer cells that undergo EMT acquire characteristics of CSCs<sup>22,23</sup>. On the other hand, it is known that during EMT process cells lose their adhesion ability with adjacent epithelial cells<sup>9</sup>. This property has been extensively used to remove mesenchymal cells from primary epithelial cell cultures following the protocol known as “differential trypsinization” developed by Owens *et al.* in 1974<sup>24</sup>. Here we report that the application of this technique in cancer cell cultures shows that cells selected by differential trypsinization differ in phenotypical and functional CSCs properties, including ALDH activity, SP proportion, xenograft tumor formation ability and metastatic potential, among others. As expected, trypsin-sensitive (TS) cancer cells subpopulations show increased CSCs properties when compared with the total population (TP) and/or the trypsin-resistant (TR) subpopulation.

## Materials and Methods

**Cell lines and cell culture.** Breast (MCF7 and MDA-MB-231) and colon (HT-29 and T84) cancer cell lines were obtained from American Type Culture Collection (ATCC) and cultured following ATCC recommendations.

**Differential trypsinization.** Cells at 60–80% of confluence were slowly washed with phosphate buffered saline (PBS) without directly flow falls on the cells. Then, 0.05% trypsin was added and incubated 2 minutes at 37 °C. Detached cells were collected in centrifuge tubes and were named as Trypsin-Sensitive 1 (TS<sub>1</sub>). The remaining attached cells were washed twice and, then, 0.25% trypsin was added. These cells were named as Trypsin-Resistant 1 (TR<sub>1</sub>). On the other hand, TS<sub>1</sub> cells were again plated for 24 hours. After that, 0.05% trypsin was added and incubated for 2 minutes at 37 °C. These detached cells were named as Trypsin-Sensitive 2 (TS<sub>2</sub>) (Fig. 1A).

In order to separate more strictly cells with stem-like and no stem-like properties, cells were grown until 60–80% of confluence and washed slowly with PBS. After obtaining the TS<sub>1</sub> subpopulation, remaining cells attached to the dishes were washed twice with PBS and incubated with 0.05% trypsin for 4 minutes at 37 °C. Cells detached from this trypsinization were discarded. Dishes with remaining trypsin-resistant cells were named as TR<sub>2</sub> (Fig. 1B). Total population (TP) was used as control cells.

**Flow cytometry analyses.** ALDEFUOR assays (Stem Cell Technologies) to detect ALDH1 activity were performed according to manufacturer's instructions. Diethylaminobenzaldehyde (DEAB) was used as an ALDH1 inhibitor to set ALDH1 gates. Cell surface levels were determined with anti-human antibodies CD44-PE, CD24-APC, CD133-APC, CD326-FITC, CK18-FITC and CK20-FITC (Miltenyi Biotec). All samples were analyzed on a FACS CANTO II (BD Biosciences) using the FACS DIVA software.


**Side population assays.** Hoechst 33342 exclusion (Side Population) assays were carried out as previously described<sup>21,25</sup>.

**Sphere-forming assay.**  $3 \times 10^3$  cells were washed with PBS and resuspended in spheres culture medium (DMEM:F12, 1% penicilin/streptomycin, B27, 10 μg/mL ITS, 1 μg/mL Hydrocortisone, 4 ng/mL Heparin, 10 ng/mL EGF, 20 ng/mL FGF) in ultra-low adherence 24-well plates (Corning). Spheres > 75 μM diameter were counted after 6 days by light microscopy.

For the secondary sphere-forming assay, cells from primary spheres were collected by centrifugation, then dissociated with trypsin-EDTA and mechanically disrupted with a pipette.  $10^3$  single cells were plated and resuspended in spheres culture medium in ultra-low adherence 24-well plates. Spheres > 75 μM diameter were counted after 6 days by light microscopy.

**Soft agar assay.**  $10^4$  cells were seeded in 0.4% cell agar base layer, which was on top of 0.8% base agar layer in 6-well culture plates. Cells were then incubated for a further 21 days at 37 °C and 5% CO<sub>2</sub>. Cell colony formation was then examined under a light microscope after staining with 0.01% Crystal Violet (Sigma-Aldrich).

**qRT-PCR.** Total RNA extraction and qRT-PCR assays were done following standard protocols. See Supplementary Material and Methods for more details. Primer sequences are listed in Supplementary Table 1.



**Figure 1. Differential trypsinization protocols.** (A) Isolation of  $TS_1$ ,  $TS_2$  and  $TR_1$  subpopulations, used for Aldefluor assays, Hoechst 33342, surface markers, spheres and colonies formation ability. (B) Improved protocol to isolate highly attached cells ( $TR_2$ ) used for Aldefluor, qRT-PCR and *in vivo* assays. Red balls represent cells with higher CSC-like properties and green balls cells with a non CSC-like phenotype.

**Proliferation assay.** Different subpopulations ( $TP$ ,  $TS_1$  and  $TR_2$ ) were seeded in 24-well plates in medium supplemented with 10% FBS for 6 days. Cells were incubated with MTT every two days and the fluorescence was measured at 570 nm.

**Lentivirus transfections.** 293T cells were co-transfected with a lentiviral vector encoding for the firefly luciferase and the red fluorescent protein td-Tomato (L2T)<sup>26</sup>, a packaging vector (psPAX2) and an envelope vector (pCMV-VSVG) using lipofectamine transfection reagent (Life Technologies). Viral particles produced from 293T cells were collected and used to infect MDA-MB-231 cells. Briefly, supernatant recovered after 48h from 293T transfected cells was filtered by a 0.45  $\mu$ m pore membrane and added to MDA-MB-231 plated cells supplemented with 4  $\mu$ g/mL polybrene (Sigma-Aldrich). After viral infection, td-Tomato<sup>+</sup> cells were selected for stable integration of the transfects by FACS.

**Mouse models.** Tumor-initiation experiments and experimental lung metastasis assays are detailed in Supplementary Materials and Methods. All animal studies were performed according to protocols reviewed and approved by the Institutional Animal Care and Use Committee at the University of Granada.

**Histological and immunological analysis.** Described in detail in Supplementary Materials and Methods.

**Statistical analysis.** All graphed data are presented as mean  $\pm$  SD from at least three experiments. two-tailed Student's t-tests and two-way ANOVA were used to determine statistical differences for *in vitro* and *in vivo* experiments respectively. P-values  $< 0.05$  were considered statistically significant in all cases.

## Results

**Trypsin-sensitive subpopulation displays CSC-like phenotypic properties.** To test whether TS subpopulations are enriched in CSC-like properties, we determined the ALDH activity, the rate of SP and specific breast and colon CSC-related cell surface markers (Fig. 2). Regarding to ALDH activity, both TS<sub>1</sub> and TS<sub>2</sub> subpopulations presented a significantly higher proportion of ALDH positive cells than TP. In contrast, TR<sub>1</sub> subpopulation displayed a lesser ALDH activity, although this change was not significant when compared to the TP (Fig. 2A, Supplementary Fig. S1A and Supplementary Table 2).

Accordingly, the rate of SP in TS subpopulations was significantly higher than in both TP and TR<sub>1</sub> cells for all cell lines tested. Thus, TS<sub>1</sub> cells showed values ranged from 48.6% up to 70.5% and TS<sub>2</sub> from 82.3% up to 89.9%. However, TP cells displayed percentages comprising between 3.9% and 13.2% (Fig. 2B, Supplementary Fig. S1B and Supplementary Table 3).

Moreover, we determined CD44/CD24 expression for breast and CD44/CD133/CD326 expression for colon cancer cell lines to study the proportion of cancer cells with a CSC phenotype in the different subpopulations. Flow cytometry analysis indicated that in the MCF7 cell line, TS<sub>1</sub> and TS<sub>2</sub> subpopulations showed a significantly higher CD44<sup>+</sup>/CD24<sup>-</sup> proportion than TP and TR<sub>1</sub> (Fig. 2C). However, no significant differences were found for these markers in the different subpopulations of the MDA-MB-231 breast cancer cell line, probably due to the high proportion of cells with this phenotype in the TP (Fig. 2D). In HT-29 colon cancer cells, the expression of CD44<sup>+</sup>/CD133<sup>+</sup>/CD326<sup>+</sup> was significantly higher for TS<sub>1</sub> and TS<sub>2</sub> in comparison to TR<sub>1</sub>, although only TS<sub>2</sub> showed a significant increase in the proportion of cells with this phenotype when compared to the TP (Fig. 2E). It is important to note that HT-29 cells showed two different subpopulations based on CD326 expression, and that CD326<sup>high</sup> and CD326<sup>low</sup> HT-29 cells were separated prospectively by differential trypsinization, being the TS subpopulation composed for CD326<sup>high</sup> cells (Supplementary Fig. S1C). In regards to T84 colon cancer cells, TS<sub>1</sub> and TS<sub>2</sub> showed a higher enrichment in cells with a CD44<sup>+</sup>/CD326<sup>+</sup> phenotype, even when their expression was studied together or separate (Fig. 2F). Differences in the expression of CD133 were not significant; however, this cell surface marker was more expressed in TS subpopulations (Supplementary Fig. S1D).

**Trypsin-sensitive subpopulation possesses higher self-renewal ability and clonogenicity.** We next tested *in vitro* functional characteristics of these cell subpopulations isolated by differential trypsinization. We studied the anchorage-independent growth of TS and TR subpopulations under free-serum conditions to determine their self-renewal ability; and also their clonogenic capacity by colony-formation assay in soft agar. As it is shown in Fig. 3A,B, tumorspheres were formed more efficiently from TS<sub>1</sub> and TS<sub>2</sub> than TR<sub>1</sub> and TP cells in all cell lines; therefore TS subpopulations have a higher capacity of self-renewal. Moreover, TR<sub>1</sub> subpopulation formed significantly less spheres than TP for MCF7, MDA-MB-231 and T84 (Fig. 3A,B).


We also performed a secondary sphere-formation assay by dissociating primary spheres formed by TS<sub>1</sub>, TR<sub>1</sub> and TP cells, as indicated in the Materials and Methods section. As it is shown in Fig. 3C for the breast cancer MDA-MB-231 and colon cancer T84 cell lines, the number of cells with the ability to form secondary spheres was higher in primary spheres formed by the TS<sub>1</sub> subpopulation, while those formed by TR<sub>1</sub> were poorly enriched in sphere-forming cells. In addition, TS subpopulations showed a significant higher capacity to form colonies in soft agar than TP for all cell lines studied (Fig. 3D). These data are in concordance with our previous results obtained from the primary sphere formation assay and support our prior conclusion about the higher self-renewal ability of the TS subpopulation.

All together, these results indicate that cells isolated by differential trypsinization differ in their enrichment in cells with functional CSC-like properties. Furthermore, the rate of these cells in the subpopulations isolated is well maintained when cells are cultured in suspension in FBS-free media.


## Isolation of cancer cells with stem- and no stem-like properties based on their adhesion capacity.

As we shown above, we obtained a cell subpopulation enriched for CSCs features based in their lower adhesion capacity to the cell culture surface. The amount of cells detached after the first trypsinization was very low and the rest of attached cells was very similar to the total population. For this reason, to demonstrate that it is possible to separate CSCs and cancer cells no stem based on their sensitivity to trypsin digestion, we developed another protocol. After the first trypsinization we recovered the TS<sub>1</sub> subpopulation and remaining attached cells were trypsinized again with the same trypsin dilution indicated above, but in this case for 4 minutes. Cells that were detached by this last trypsinization were discarded and cells still attached were recovered and named as TR<sub>2</sub>, as described in the Material and Methods section (Fig. 1B). As it is shown in Fig. 4A and Supplementary Fig. S2, TP and subpopulations TS<sub>1</sub> and TR<sub>2</sub> differed in ALDH activity. In concrete, TS<sub>1</sub> subpopulation was enriched in cells with a high ALDH activity, with purity higher than 90%, and TR<sub>2</sub> showed a lack of ALDH activity in both MDA-MB-231 and MCF7 (Fig. 4A and Supplementary Fig. S2). As it is shown the purity of ALDH<sup>+</sup> cells obtained by differential trypsinization from MCF7 cells was similar to the enrichment obtained by FACS (Supplementary Fig. S2).

On the other hand, we also studied the expression levels of both the luminal cytokeratin 18 and the intestinal epithelium differentiation cytokeratin 20 for breast and colon cancer cells, respectively, after differentiation of TS<sub>1</sub> cells in media containing FBS for 7 days when grown attached to the cell culture surface. As it is shown in Supplementary Fig. S3, TS<sub>1</sub> cells cultured under these conditions recovered the expression levels of these



**Figure 2. Phenotypic properties of breast and colon cancer cell subpopulations isolated by differential tripsinization.** Percentage of ALDH<sup>+</sup> (A) and SP (B) cells determined in subpopulations of MCF7, MDA-MB-231, HT-29 and T84 cancer cell lines. (C,D) Percentage of CD44<sup>+</sup>/CD24<sup>-</sup> cells in TR<sub>1</sub>, TP, TS<sub>1</sub> and TS<sub>2</sub> isolated from MCF7 (C) and MDA-MB-231 (D) breast cancer cells measured by flow cytometry. (E) Co-expression of CD44, CD133 and CD326 in HT-29 cells isolated by differential tripsinization and in the TP. (F) Flow cytometry for CD44 and CD326 expression, alone or together, in T84 cells. Data are graphed as mean  $\pm$  SD from at least two different experiments carried-out by triplicates (\*\*P < 0.01; \*P < 0.05). See also Supplementary Fig. S1.




**Figure 3. Tumorsphere- and colony-forming ability of breast and colon cancer cell subpopulations isolated by differential trypsinization.** (A) Representative images of mammospheres formed from different MCF7 subpopulations. (B) Number of spheres formed by different subpopulations of each cell line. (C) Secondary sphere formation assay performed in MDA-MB-231 and T84 cells selected by differential trypsinization and compared to the TP. Data shown as mean  $\pm$  SD (\*\* $P < 0.01$ ; \* $P < 0.05$ ). (D) Number of colonies formed by TP and TS<sub>1</sub> of each cell line. Data are represented as mean  $\pm$  SD (\*\* $P < 0.01$ ; \* $P < 0.05$ ).


cytokeratins at similar values than those observed in the TP. These results are an indicator of the ability of the TS<sub>1</sub> cells to recapitulate the heterogeneity of the parental cell line.

**Trypsin-sensitive subpopulation expresses higher levels of EMT- and pluripotency- associated genes.** The enrichment of cancer cells with stem cell-like properties in cells which show low adherence to plastic surface may be due to an EMT process, which is associated with metastasis. To understand the molecular changes underlying the different characteristics of these cell subpopulations, we analyzed the expression of genes related to the EMT process and/or pluripotency on MDA-MB-231 cells.

qRT-PCR studies demonstrated that all genes assayed were expressed differentially in the TS<sub>1</sub> and the TR<sub>2</sub> cell subpopulations. *SNAIL*, *SLUG*, *VIMENTIN*, *N-CADHERIN*, *CXCL10*, *OCT4* and *BMI1* were overexpressed in the TS<sub>1</sub> subpopulation when compared to the TP, and underexpressed in the TR<sub>2</sub> subpopulation (Fig. 4B). In



**Figure 4.** ALDH activity, mRNA and miRNA expression in enriched subpopulations of MDA-MB-231 cells isolated by their different adhesion capacity. (A) Aldefluor assay performed in TR<sub>2</sub>, TP and TS<sub>1</sub> MDA-MB-231 cells. See also Supplementary Fig. S2. (B) qRT-PCR analysis for the expression of CSCs and EMT-related genes in different subpopulations of MDA-MB-231 cells. Data are normalized to 1 for TP using *GAPDH* as internal control, and graphed as mean  $\pm$  SEM (n = 3) (\*\*P < 0,01; \*P < 0,05). (C) Differential expression of miRNAs related to CSC phenotype and/or EMT in MDA-MB-231 cells isolated by differential trypsinization. Data are normalized to 1 for TP using miR-24c-3p as internal control, and graphed as mean  $\pm$  SEM (n = 3) (\*\*P < 0,01; \*P < 0,05).



**Figure 5. Proliferation assay.** Proliferation curves of TS<sub>1</sub>, TR<sub>2</sub> and TP cells cultured for 6 days in media containing FBS, and measured using MTT every 2 days in cultures seeded with an equal number of cells at day 0. Data are represented as absorbance at 570 nm and shown as mean  $\pm$  SD (\*\*P < 0.01; \*P < 0.05).

contrast, expression levels of *CLAUDIN1* and *E-CADHERIN* were higher in TR<sub>2</sub> cells and much lower in the TS<sub>1</sub> subpopulation (Fig. 4B).


On the other hand, the expression patterns of several miRNAs related with EMT and/or pluripotency also differ between these two cell subpopulations isolated by differential trypsinization. The TR<sub>2</sub> subpopulation showed a significant increase in the expression levels of miR-93-5p, miR-34a-5p, miR-100-5p and miR-34c-5p (Fig. 4C). However, all of these miRNAs were downregulated in the TS<sub>1</sub> subpopulation when compared to the TP, although not all of them were statistically significant (Fig. 4C). In contrast, the expression of miR-21-5p was higher in TS<sub>1</sub> and lower in TR<sub>2</sub> cells when compared to the TP (Fig. 4C).

Moreover, the proliferation assay demonstrated that both TR<sub>2</sub> and TP subpopulations grow faster than TS<sub>1</sub> for all tumor cell lines (Fig. 5), showing that the TS<sub>1</sub> subpopulation has a lower proliferation rate *in vitro*.

**Trypsin-sensitive subpopulation is enriched in tumor-initiating cells.** To confirm the results observed *in vitro*, TS<sub>1</sub> and TR<sub>2</sub> subpopulations were isolated from MDA-MB-231 cells, injected subcutaneously in NSG mice and compared with the TP in a limiting dilution *in vivo* assay. The overall survival of mice injected with TS<sub>1</sub> cells was lower than for the other groups (Fig. 6A). When  $5 \times 10^3$  TS<sub>1</sub>, TP or TR<sub>2</sub> cells were injected, the overall survival of mice was 63 and 77 days, for TS<sub>1</sub> and TP respectively, while 2 out of 6 mice injected with the TR<sub>2</sub> subpopulation were still alive at day 81, the end-point of the experiment (Fig. 6A). Furthermore, tumor volume was higher after injection of TS<sub>1</sub> cells, while tumors formed by TR<sub>2</sub> cells were smaller (Fig. 6B), being these results not explained by a global mitogenic effect since TR<sub>2</sub> cells have higher proliferation rate than TS<sub>1</sub> cells (Fig. 5). Similar results were observed when  $1.5 \times 10^4$  cells were injected, however the overall survival was shorter and the tumor size bigger for all groups, as it was expected (Fig. 6A,B). All together, these data demonstrate that TS cells are enriched in CSCs with a high tumor-initiating capacity while the TR subpopulation is composed mainly by non CSC-like cells.

**Trypsin-sensitive subpopulation generates more metastasis than trypsin-resistant subpopulation after tail vein injection.** To further demonstrate the higher aggressiveness of the TS subpopulation, we compared the metastatic ability of both cell subpopulations isolated by differential trypsinization (TS<sub>1</sub> and TR<sub>2</sub>) with the TP using MDA-MB-231 L2T cells. When  $2.5 \times 10^5$  TS<sub>1</sub> cells were injected into the tail vein of NSG mice, 5 of 6 animals developed lung metastasis, however only 4 and 2 of 6 animals developed metastasis when TP or TR<sub>2</sub> cells, respectively, were injected (IVIS images from week 3 are shown in Fig. 7A). In addition, the TS<sub>1</sub>





**Figure 6.** Overall survival and subcutaneous xenograft tumor formation (A) Kaplan-Meier curve for overall survival of NSG mice injected with  $5 \times 10^3$  cells (left) and  $1.5 \times 10^4$  cells (right) from TS<sub>1</sub>, TR<sub>2</sub> or TP. (B) Tumor volume (mm<sup>3</sup>) of subcutaneous xenograft tumors formed by  $5 \times 10^3$  and  $1.5 \times 10^4$  cells from TS<sub>1</sub>, TR<sub>2</sub> and TP in NSG mice. Data are shown as mean  $\pm$  SD (\*\*P < 0.01; \*P < 0.05).


subpopulation, that showed the lowest proliferation rate *in vitro* (Fig. 5), caused a more rapid increase in tumor bioluminescence, demonstrating their higher metastatic ability (Fig. 7A). After 4 weeks, animals were sacrificed and lungs harvested for further analysis (Fig. 7B). Lungs from mice injected with TS<sub>1</sub> cells showed more pulmonary metastatic nodules than these from TP or TR<sub>2</sub> cells (representative images, Fig. 7C). Furthermore, histological and immunohistochemical analysis of lungs demonstrated that metastatic nodules formed by TS<sub>1</sub> cells were bigger when compared to the TP, and smaller when TR<sub>2</sub> cells were injected (Fig. 7D,E), being these differences in size independent of a global mitogenic effect (Fig. 5). This further demonstrates the higher metastatic ability of the TS subpopulation and that the TR subpopulation is composed by non CSC-like cells.

## Discussion

In this work, we demonstrate that cultured cancer cells possess low adherent cancer cell subpopulations with stemness properties. Therefore, differential trypsinization, an extended methodology for the establishment of primary epithelial cell cultures<sup>24,27</sup>, can be applied to isolate breast and colon cancer cells with CSCs properties *in vitro* and *in vivo*, and likewise for other cancer types with an epithelial origin. In this work, we demonstrate that two distinct subpopulations of cancer cells can be isolated by this protocol: i) a subpopulation with CSCs properties and lower adherence ability (TS subpopulation); ii) and a highly adherent subpopulation enriched in non CSC-like cells (TR subpopulations).

Breast and colon cancer TS subpopulation is enriched in cells with high ALDH activity, and greater SP rate, being these characteristics associated with CSCs properties. The isolation of a subpopulation with high ALDH activity has been demonstrated to show higher tumorigenic potential in both breast and colon cancers<sup>18,20</sup>. Regarding to Hoechst 33342 dye efflux, different studies have shown that the SP phenotype is enriched in cancer stem-like cells in different tumors, including breast and colon cancers<sup>19,21</sup>. Moreover, the ability to exclude Hoechst 33342 is associated with an upregulation of ATP-binding cassette transporters that confer multidrug resistance, a characteristic of CSCs<sup>28</sup>.

However, the characterization of CSCs by the expression of specific cell surface markers is the most extended method to identify and isolate this cancer cell subpopulation. We have demonstrated that MCF7 breast cancer cells from the TS subpopulation are enriched in cells with a CD44<sup>+</sup>/CD24<sup>-</sup> phenotype, which is characteristic of breast



**Figure 7. Experimental lung metastasis assay.** (A) IVIS images of lung metastasis formed after tail vein injection of TP, TR<sub>2</sub> and TS<sub>1</sub> MDA-MB-231 L2T cells (up). Measure of photon flux is graphed as mean ± SEM (down). (B) Fluorescence of metastatic lungs *ex vivo*. (C) Representative optical images of lung metastasis for a healthy mice (control) and lungs extracted from NSG mice injected with different subpopulations of MDA-MB-231 cells obtained by differential trypsinization. (D,E) Histological (D) and immunohistochemical (E) images of lungs obtained from healthy mice (control) and mice injected with TR<sub>2</sub>, TP and TS<sub>1</sub> cells (left to right).

CSCs<sup>13</sup>. On the other hand, HT-29 and T84 TS colon cancer cells are enriched in CD44<sup>+</sup>, CD133<sup>+</sup> and/or CD326<sup>+</sup> cells. Colon CSCs were firstly identified based on the expression of CD133, being determined that the ability to develop tumors in immunodeficient NOD/SCID mice was restricted to CD133<sup>+</sup> cells<sup>15,16</sup>. In a latter study, Dalerba *et al.* demonstrated that the ability to engraft in immunodeficient mice was restricted to a minority subpopulation CD326<sup>high</sup>/CD44<sup>+</sup>. Furthermore, tumors originated from CD326<sup>high</sup>/CD44<sup>+</sup> cells maintained a differentiated

phenotype and reproduced the full morphologic and phenotypic heterogeneity of their parental lesions<sup>17</sup>. Regarding to MDA-MB-231 TS cells, we did not see a significant increase in the CD44<sup>+</sup>/CD24<sup>-</sup> subpopulation, however the percentage in all groups was very high, around 80%, which is in concordance with the highly invasive/metastatic skills of this triple negative breast cancer cell line<sup>29</sup>.

Breast and colon cancer cells isolated by differential trypsinization also differ in their self-renewal ability. CSC self-renewal can be assayed *in vitro* by tumor spheres and holoclone colonies formation assays<sup>30</sup>. The TS subpopulation obtained from both breast and colon cancer cell lines generated more colonies in soft agar and spheres in low attachment plates under serum deprivation. It has been demonstrated that colon CSCs enriched in CD133<sup>+</sup> cells form more colonies in soft agar used as indicator of their higher tumor-initiating ability<sup>31</sup>. In addition, it has been shown that MDA-MB-231 breast cancer cells enriched in cancer-initiating stem cells have higher colony-formation ability<sup>32</sup>. On the other hand, CSCs have the ability to form spheres in low-attachment culture surfaces under free serum conditions and this kind of culture conditions increases the percentage of cells with a CSC phenotype based on surface markers expression<sup>25,33</sup>. In contrast, the number of colonies and spheres formed from TR cells was significantly lower than in the TP, indicating the lower self-renewal ability and therefore, the non CSC-like properties of this cancer cell subpopulation selected by a higher adhesion capability to the cell culture surface.

All these *in vitro* studies for phenotypical and functional properties of CSCs were notably increased in the TS subpopulations for all cell lines, except for CD44<sup>+</sup>/CD24<sup>-</sup> expression in MDA-MB-231 breast cancer cells that is basally high in TP cells. For this reason, we selected this cell line to perform further studies. qRT-PCR analysis of different mRNA and miRNA related with EMT, self-renewal and/or aggressiveness demonstrated differences in their expression between TR and TS subpopulations. The gene profile of MDA-MB-231 TS cells was more associated with a mesenchymal phenotype while the TR subpopulation was more related with an epithelial phenotype. During the EMT process, cancer cells lose their attachment to the epithelial niche and acquire a mesenchymal phenotype which is characteristic of metastatic cancer cells<sup>34</sup>. Moreover, the triple-negative MDA-MB 231 breast cancer cell line, which overexpresses EGFR<sup>35</sup>, has potent and reproducible migratory responses<sup>36</sup>. MDA-MB-231 TS cells showed a lack of expression of *E-CADHERIN* and *CLAUDIN*. The loss by carcinoma cells of E-cadherin, a key cell-to-cell adhesion molecule which establish adherent junctions with adjacent epithelial cells, is the best characterized alteration during the EMT process<sup>9,34</sup>. In regard to claudin expression, a phenotype claudin-low is associated with enrichment for EMT markers, immune response genes, cancer stem cell-like features and poor outcome in breast cancer<sup>37</sup>. In addition, the TS subpopulation also shows a higher expression of several transcription factors that modulates the EMT, such as *SNAIL* or *SLUG*, and other mesenchymal markers including *N-CADHERIN* and *VIMENTIN*<sup>38</sup>. In contrast, the expression of these genes was contrary regulated in MDA-MB-231 TR cells, indicating their more epithelial features. In fact, we have recently demonstrated important role of Vimentin/Slug EMT markers in tumor growth of primary breast cancer patients and in circulating tumor cells (CTCs) EGFR<sup>+</sup> from cytokeratin negative non-metastatic breast cancer patients<sup>39</sup>.

Certain ES-TFs, such as Oct4, Sox2 and Nanog, which are master regulators of ES self-renewal and pluripotency, are also upregulated in CSCs<sup>40</sup>. *OCT4* expression was measured in MDA-MB-231 cells, demonstrating that it is overexpressed in the TS subpopulation. Interestingly, a recent study showed that Oct4 is associated with poor prognosis and that positively regulates the EMT process, contributing to breast cancer metastasis<sup>38</sup>. Furthermore, CSCs share similarities with normal stem cells in the regulation of the Wnt, Notch and Hedgehog signaling pathways, and the expression of several genes of the polycomb family, including *BMI-1*, or the *HOX* family among others which are involved in stem cells self-renewal<sup>4</sup>. *BMI-1*, which is overexpressed in TS cells, has been also related with the EMT process and drug resistance<sup>41</sup>. Moreover, *CXCL10* is expressed in basal tumors as compared with ER<sup>+</sup> tumors, being associated with a higher tumor grade and a poor prognosis of breast cancer<sup>42</sup>.

On the other hand, miRNAs play critical regulatory roles in a wide range of biologic and pathologic processes, and miRNA expression profiling reveals substantial differences between cancer and normal tissue, and among different cancer types<sup>43</sup>. We studied the expression patterns of different miRNAs that have been previously shown to be related with CSCs properties, EMT, metastasis and poor outcome. For example, the TR subpopulation overexpresses miR-93, which inhibits cell proliferation, the capacity to form colonies<sup>44</sup> and promotes mesenchymal-to-epithelial transition (MET)<sup>45</sup>. miR-34a-5p and miR-34c-5p are downregulated in TS cells and upregulated in the TR subpopulation. miR-34 family are reportedly as tumor-suppressor miRNAs implicated in reduced CSC properties and increased sensitivity to drug treatment by directly targeting *NOTCH1*<sup>46</sup>. miR-100 is also upregulated in the TR subpopulation, and its expression levels relate to the cellular differentiation state, with lowest expression in cells displaying stem cell markers<sup>47</sup>. In addition, the expression of miR-21, a well known miRNA which is dysregulated in several types of cancer and plays a key role in carcinogenesis, recurrence and metastasis<sup>48</sup>, is increased in the TS subpopulation and decreased in TR cells.

All together, these data demonstrate that differential trypsinization of breast and colon cancer cell cultures allows the isolation of two subpopulations (TR and TS) that differ in their CSC-like cells properties. TS cells show increased ALDH activity, SP proportion and CSC-like phenotype. This subpopulation is enriched in cells that have followed an EMT process and possess high self-renewal ability. Moreover, TS cells show higher tumorsphere- and colony-formation ability *in vitro*; and tumorigenic and metastatic potential *in vivo*. In contrast, the TR subpopulation is mainly composed by non CSC-like cells with a lower tumorigenic capacity both *in vitro* and *in vivo*. In a previous study carried-out by Walia and Elbe, it was shown that the TS subpopulation, obtained by differential trypsinization from transformed human mammary epithelial cells, was enriched in stem cell properties<sup>49</sup>. In a more recent study, this methodology was used to isolate a subpopulation of cells with a mesenchymal phenotype from an oncogenic transformed human mammary epithelial cell line<sup>50</sup>. However, these studies were limited to determine EMT markers expression, mammosphere-forming ability, drug resistance and CD44/CD24 expression, and were carried-out in a well differentiated oncogenic transformed human mammary epithelial cell line.

## Conclusion

In summary, our results evidence that cultured cancer cells possess low adherent cell subpopulations with stemness properties and with high tumorigenic and metastatic abilities. We show for the first time that differential trypsinization, a new, non-aggressive, easy, inexpensive and reproducible methodology to isolate prospectively breast and colon cancer stem-like cells for subsequent biological studies, high throughput screening therapeutic strategies targeting CSCs and preclinical assays.

## References

1. Tirino, V. *et al.* Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. *FASEB J* **27**, 13–24, doi: 10.1096/fj.12-218222 (2013).
2. O'Brien, C. A., Kreso, A. & Dick, J. E. Cancer stem cells in solid tumors: an overview. *Semin Radiat Oncol* **19**, 71–77, doi: 10.1016/j.semradi.2008.11.001 (2009).
3. Zeineddine, D., Hammoud, A. A., Mortada, M. & Boeuf, H. The Oct4 protein: more than a magic stemness marker. *Am J Stem Cells* **3**, 74–82 (2014).
4. Liu, S. *et al.* Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. *Cancer Res* **66**, 6063–6071, doi: 10.1158/0008-5472.CAN-06-0054 (2006).
5. O'Brien, C. A., Kreso, A. & Jamieson, C. H. Cancer stem cells and self-renewal. *Clin Cancer Res* **16**, 3113–3120, doi: 10.1158/1078-0432.CCR-09-2824 (2010).
6. Chhabra, R. & Saini, N. MicroRNAs in cancer stem cells: current status and future directions. *Tumour Biol* **35**, 8395–8405, doi: 10.1007/s13277-014-2264-7 (2014).
7. Visvader, J. E. & Lindeman, G. J. Cancer stem cells: current status and evolving complexities. *Cell Stem Cell* **10**, 717–728, doi: 10.1016/j.stem.2012.05.007 (2012).
8. Raha, D. *et al.* The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. *Cancer Res* **74**, 3579–3590, doi: 10.1158/0008-5472.CAN-13-3456 (2014).
9. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674, doi: 10.1016/j.cell.2011.02.013 (2011).
10. Ombrato, L. & Malanchi, I. The EMT universe: space between cancer cell dissemination and metastasis initiation. *Crit Rev Oncol* **19**, 349–361, doi: 10.1615/CritRevOncol.2014011802 (2014).
11. Talmadge, J. E. & Fidler, I. J. AACR centennial series: the biology of cancer metastasis: historical perspective. *Cancer Res* **70**, 5649–5669, doi: 10.1158/0008-5472.CAN-10-1040 (2010).
12. Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. *Cell* **147**, 275–292, doi: 10.1016/j.cell.2011.09.024 (2011).
13. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* **100**, 3983–3988, doi: 10.1073/pnas.0530291100 (2003).
14. Azzam, D. J. *et al.* Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in gamma-secretase inhibitor drug responses. *EMBO Mol Med* **5**, 1502–1522, doi: 10.1002/emmm.201302558 (2013).
15. O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* **445**, 106–110, doi: 10.1038/nature05372 (2007).
16. Ricci-Vitiani, L. *et al.* Identification and expansion of human colon-cancer-initiating cells. *Nature* **445**, 111–115, doi: 10.1038/nature05384 (2007).
17. Dalerba, P. *et al.* Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci U S A* **104**, 10158–10163, doi: 10.1073/pnas.0703478104 (2007).
18. Ginestier, C. *et al.* ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* **1**, 555–567, doi: 10.1016/j.stem.2007.08.014 (2007).
19. Haraguchi, N. *et al.* Cancer stem cells in human gastrointestinal cancers. *Hum Cell* **19**, 24–29, doi: 10.1111/j.1749-0774.2005.00004.x (2006).
20. Huang, E. H. *et al.* Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res* **69**, 3382–3389, doi: 10.1158/0008-5472.CAN-08-4418 (2009).
21. Britton, K. M., Kirby, J. A., Lennard, T. W. & Meeson, A. P. Cancer stem cells and side population cells in breast cancer and metastasis. *Cancers (Basel)* **3**, 2106–2130, doi: 10.3390/cancers3022106 (2011).
22. Liu, X. & Fan, D. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. *Curr Pharm Des* **21**, 1279–1291, doi: 10.2174/138161282166614121115611 (2015).
23. Mani, S. A. *et al.* The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* **133**, 704–715, doi: 10.1016/j.cell.2008.03.027 (2008).
24. Owens, R. B., Smith, H. S. & Hackett, A. J. Epithelial cell cultures from normal glandular tissue of mice. *J Natl Cancer Inst* **53**, 261–269 (1974).
25. Kanwar, S. S., Yu, Y., Nautiyal, J., Patel, B. B. & Majumdar, A. P. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. *Mol Cancer* **9**, 212, doi: 10.1186/1476-4598-9-212 (2010).
26. Liu, H. *et al.* Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. *Proc Natl Acad Sci USA* **107**, 18115–18120, doi: 10.1073/pnas.1006732107 (2010).
27. Garcia-Posadas, L., Arranz-Valsero, I., Lopez-Garcia, A., Soriano-Romani, L. & Diebold, Y. A new human primary epithelial cell culture model to study conjunctival inflammation. *Invest Ophthalmol Vis Sci* **54**, 7143–7152, doi: 10.1167/iops.13-12866 (2013).
28. Natarajan, K., Xie, Y., Baer, M. R. & Ross, D. D. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. *Biochem Pharmacol* **83**, 1084–1103, doi: 10.1016/j.bcp.2012.01.002 (2012).
29. Xu, J., Prosperi, J. R., Choudhury, N., Olopade, O. I. & Goss, K. H. Beta-catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. *PLoS One* **10**, e0117097, doi: 10.1371/journal.pone.0117097 (2015).
30. Shigeishi, H. *et al.* Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3beta influenced by CD44 and RHAMM. *Stem Cells* **31**, 2073–2083, doi: 10.1002/stem.1418 (2013).
31. Puglisi, M. A. *et al.* Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. *Eur Rev Med Pharmacol Sci* **13** Suppl 1, 55–62 (2009).
32. Zhao, D. *et al.* VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. *Oncogene*, doi: 10.1038/onc.2014.257 (2014).
33. Rappa, G. *et al.* Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. *Exp Cell Res* **314**, 2110–2122, doi: 10.1016/j.yexcr.2008.03.008 (2008).
34. Cervantes-Arias, A., Pang, L. Y. & Argyle, D. J. Epithelial-mesenchymal transition as a fundamental mechanism underlying the cancer phenotype. *Vet Comp Oncol* **11**, 169–184, doi: 10.1111/j.1476-5829.2011.00313.x (2013).
35. Corkery, B., Crown, J., Clynes, M. & O'Donovan, N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. *Ann Oncol* **20**, 862–867, doi: 10.1093/annonc/mdn710 (2009).

36. Price, J. T., Tiganis, T., Agarwal, A., Djakiew, D. & Thompson, E. W. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. *Cancer Res* **59**, 5475–5478 (1999).
37. Sabatier, R. *et al.* Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. *Mol Cancer* **13**, 228, doi: 10.1186/1476-4598-13-228 (2014).
38. Wang, D. *et al.* Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. *Oncotarget* **5**, 10803–10815 (2014).
39. Serrano, M. J. *et al.* EMT and EGFR in CTCs cyokeratin negative non-metastatic breast cancer. *Oncotarget* **5**, 7486–7497 (2014).
40. Liu, A., Yu, X. & Liu, S. Pluripotency transcription factors and cancer stem cells: small genes make a big difference. *Chin J Cancer* **32**, 483–487, doi: 10.5732/cjc.012.10282 (2013).
41. Paranjape, A. N. *et al.* Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. *BMC Cancer* **14**, 785, doi: 10.1186/1471-2407-14-785 (2014).
42. Mulligan, A. M. *et al.* Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. *Clin Cancer Res* **19**, 336–346, doi: 10.1158/1078-0432.CCR-11-3314 (2013).
43. Lu, J. *et al.* MicroRNA expression profiles classify human cancers. *Nature* **435**, 834–838, doi: 10.1038/nature03702 (2005).
44. Leal, J. A. & Leonart, M. E. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. *Cancer Lett* **338**, 174–183, doi: 10.1016/j.canlet.2012.04.020 (2013).
45. Liu, S., Clouthier, S. G. & Wicha, M. S. Role of microRNAs in the regulation of breast cancer stem cells. *J Mammary Gland Biol Neoplasia* **17**, 15–21, doi: 10.1007/s10911-012-9242-8 (2012).
46. Park, E. Y. *et al.* Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. *Cancer Res* **74**, 7573–7582, doi: 10.1158/0008-5472.CAN-14-1140 (2014).
47. Deng, L. *et al.* MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development. *Cancer Res* **74**, 6648–6660, doi: 10.1158/0008-5472.CAN-13-3710 (2014).
48. Liu, J. *et al.* MicroRNA-21 is a novel promising target in cancer radiation therapy. *Tumour Biol* **35**, 3975–3979, doi: 10.1007/s13277-014-1623-8 (2014).
49. Walia, V. & Elble, R. C. Enrichment for breast cancer cells with stem/progenitor properties by differential adhesion. *Stem Cells Dev* **19**, 1175–1182, doi: 10.1089/scd.2009.0430 (2010).
50. Tam, W. L. *et al.* Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. *Cancer Cell* **24**, 347–364, doi: 10.1016/j.ccr.2013.08.005 (2013).

## Acknowledgements

We thanks Dr Gambhir's laboratory from the Standford University for providing L2T plasmid. This work was supported in part by grants from the Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (FEDER funds, projects n°. PI10/02295 and PI10/02149), the Fundación Progreso y Salud, Consejería de Salud, Junta de Andalucía (Ministry of Health, Government of Andalusia, project number PI-0533-2014) and by Consejería Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (Ministry of Economy, Innovation, Science and Employment, Government of Andalusia, excellence project number CTS-6568) providing a fellowship granted to GJ.

## Author Contributions

C.M.-T. Conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing; G.J., J.M.E., C.G.-L. Collection and/or assembly of data, data analysis and interpretation. M.A.G. Data analysis and interpretation, manuscript writing; M.A. Financial support, provision of study material; M.P.-R. Conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript; J.A.M. Conception and design, financial support, administrative support, provision of study material, data analysis and interpretation, manuscript writing and final approval of manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Morata-Tarifa, C. *et al.* Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells. *Sci. Rep.* **6**, 18772; doi: 10.1038/srep18772 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>